Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …

We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg· day− 1)
and nintedanib (200–300 mg· day− 1) in patients with idiopathic pulmonary fibrosis (IPF) …

Background: Two therapeutic options are currently available for patients with mild-to-
moderate idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. To date, there is …

Background Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …

Background Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are
scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone
was the first drug to be licensed and approved for use, followed by nintedanib. We set out …

Summary Background In this retrospective Italian study, which involved all major national
interstitial lung diseases centers, we evaluated the effect of pirfenidone on disease …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the
treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither …

Background and objective The real‐world tolerability of pirfenidone and nintedanib in non‐
clinical trial patients is unknown. Many patients with pulmonary fibrosis have significant …